Search for drugs:
Typing the drug name to query
ALVIMOPAN
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- At a dosage of 24 mg twice daily (two times the approved recommended dosage) for 7 days, ENTEREG does not prolong the QT interval to any clinically relevant extent. The potential for QTc effects at higher doses has not been studied.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
1
24091
Other ADRs
520
38381067
Odds Ratio = 3.064
Drug Property Information
ATC Code(s):
- A06AH02 - alvimopan
- A06AH -
- A06A - LAXATIVES
- A06 - LAXATIVES
- A - ALIMENTARY TRACT AND METABOLISM
Active Ingredient:alvimopan
Active Ingredient UNII:677C126AET
Drugbank ID:DB06274
PubChem Compound:5488548
CTD ID:C419502
PharmGKB:PA164754864
CAS Number:156053-89-3
Dosage Form(s):capsule
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.